Last Week in Biomedicine | June 6–13 | Part 1 of 2: Retatrutide Weight Loss, Weekly HIV Pill

A blockbuster week in biomedicine — Eli Lilly's retatrutide produced weight loss approaching bariatric surgery in Phase 3, and Gilead and Merck's once-weekly oral HIV pill cleared two Phase 3 trials. Plus the first in-vivo CRISPR therapy keeps stacking up Phase 3 wins.
In Part 1 we cover:1. Eli Lilly — Retatrutide for obesity (Phase 3)
2. Gilead Sciences and Merck — Islatravir/Lenacapavir for HIV (Phase 3)
3. Intellia Therapeutics — Lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (Phase 3)
Retatrutide is the standout. By activating three gut hormone receptors at once — GLP-1, GIP, and glucagon — it drove mean weight loss up to about 30% in the TRIUMPH-1 trial, while also improving blood sugar, knee osteoarthritis pain, and sleep apnea. If that holds up, the next generation of obesity medicineswon't just shrink waistlines, they'll treat the cluster of conditions tied to obesity.
Part 2 drops Thursday morning. Subscribe at TrialBreaks.com
#biomedicine #clinicaltrials #science #obesity #GLP1 #HIV #infectiousdisease #CRISPR #genetherapy #rarediseases #raredisease #metabolic #immunology